Publications by authors named "John Penrod"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

345

Total Likes

39

Extended Reach

44,145

Social Features

16
T
Treatment-Free Survival Over 6 Years of Follow-up in Patients With Metastatic NSCLC Treated With First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in CheckMate 227 Part 1.
Solange Peters, Meredith M Regan, Luis G Paz-Ares, Martin Reck, Hossein Borghaei, John R Penrod

J Thorac Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advancing real-world research in thoracic malignancies: learnings from the international I-O Optimise initiative.
Søren Paaske Johnsen, Paul Baas, Jens Benn Sørensen, Christos Chouaid, Frank Griesinger, John R Penrod

Future Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world treatment and retreatment patterns and outcomes in patients with advanced or metastatic non-small cell lung cancer following nivolumab monotherapy in second line or later in France: an I-O Optimise analysis.
Grégoire Justeau, Christos Chouaid, Didier Debieuvre, Clarisse Audigier-Valette, Xavier Quantin, John R Penrod

Front Oncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment-Switching Adjustment of Overall Survival in CheckMate 227 Part 1 Evaluating First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy for Metastatic Nonsmall Cell Lung Cancer.
Martin Reck, Tuli De, Luis Paz-Ares, Mark Edmondson-Jones, Yong Yuan, John R Penrod

Clin Lung Cancer· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Algorithms to identify radiotherapy intent in unresected non-metastatic non-small-cell lung cancer: an I-O Optimise analysis.
Eleanor Ralphs, Caroline Rault, Alan Calleja, Melinda J Daumont, John R Penrod

Future Oncol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pathological response in resectable non-small cell lung cancer: a systematic literature review and meta-analysis.
Nathalie A Waser, Melanie Quintana, Bernd Schweikert, Jamie E Chaft, Lindsay Berry, John R Penrod

JNCI Cancer Spectr· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modelling Health State Utilities as a Transformation of Time to Death in Patients with Non-Small Cell Lung Cancer.
Anthony J Hatswell, Mohammad A Chaudhary, Giles Monnickendam, Alejandro Moreno-Koehler, Katie Frampton, John R Penrod

Pharmacoeconomics· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world treatment patterns and survival outcomes for patients with stage III non-small cell lung cancer in Spain: a nationwide cohort study.
Mariano Provencio, Enric Carcereny, Rafael López Castro, Virginia Calvo, Delvys Rodríguez Abreu, John Penrod

Transl Lung Cancer Res· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world relationship of early end points to survival end points in patients with resectable non-small-cell lung cancer.
Eric Nadler, Anupama Vasudevan, Chuck Wentworth, Nicholas Robert, John R Penrod

Future Oncol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
General population reference values for the Functional Assessment of Cancer Therapy-Lung and PROMIS-29.
Nisha A Mohindra, John Devin Peipert, Steven I Blum, James W Shaw, John R Penrod

Cancer Med· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes.
Martin Reck, Tudor-Eliade Ciuleanu, Manuel Cobo, Michael Schenker, Bogdan Zurawski, John R Penrod

Eur J Cancer· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term comparative efficacy and safety of nivolumab plus ipilimumab relative to other first-line therapies for advanced non-small-cell lung cancer: A systematic literature review and network meta-analysis.
Kenneth O'Byrne, Evan Popoff, Firas Badin, Adam Lee, Yong Yuan, John R Penrod

Lung Cancer· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Economic Evaluation of Nivolumab Versus Docetaxel for the Treatment of Advanced Squamous and Non-squamous Non-small Cell Lung Cancer After Prior Chemotherapy in China.
Shanlian Hu, Zhiliu Tang, James P Harrison, Nadine Hertel, John R Penrod

Pharmacoecon Open· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evolution of treatment patterns and survival outcomes in patients with advanced non-small cell lung cancer treated at Frankfurt University Hospital in 2012-2018.
Andrea Wolf, Jan A Stratmann, Shabnam Shaid, Nicolas Niklas, Alan Calleja, John R Penrod

BMC Pulm Med· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness of Nivolumab in Second-Line and Later in Patients with Advanced Non-Small Cell Lung Cancer in Real-Life Practice in France and Germany: Analysis of the ESME-AMLC and CRISP Cohorts.
Christos Chouaid, Michael Thomas, Didier Debieuvre, Isabelle Durand-Zaleski, Stefan Zacharias, John R Penrod

Cancers (Basel)· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adverse events and clinical outcomes in patients treated with PD-(L)1 blockade for advanced non-small-cell lung cancer.
Yan Zhang, Charlotte Doran, Trong Kim Le, Brian Dreyfus, Nina Kola, John R Penrod

Future Oncol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of immune checkpoint inhibitors on the management of locally advanced or metastatic non-small cell lung cancer in real-life practice in patients initiating treatment between 2015 and 2018 in France and Germany.
Frank Griesinger, Maurice Pérol, Nicolas Girard, Isabelle Durand-Zaleski, Stefan Zacharias, John R Penrod

Lung Cancer· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correlations between objective response rate and survival-based endpoints in first-line advanced non-small cell lung Cancer: A systematic review and meta-analysis.
Sarah Goring, Nebibe Varol, Nathalie Waser, Evan Popoff, Greta Lozano-Ortega, John R Penrod

Lung Cancer· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness analysis of nivolumab plus ipilimumab plus two cycles of platinum-doublet chemotherapy versus platinum-doublet chemotherapy alone for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States.
Maria Polyzoi, Hera Sandhu, Johan Maervoet, Yong Yuan, Mohammad A Chaudhary, John R Penrod

J Med Econ· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness analysis of nivolumab plus ipilimumab versus platinum-doublet chemotherapy for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States.
Malin Berling, Mohammad A Chaudhary, Yong Yuan, Nebibe Varol, Peter Dale, John R Penrod

J Med Econ· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world effectiveness of immunotherapies in pre-treated, advanced non-small cell lung cancer Patients: A systematic literature review.
Ariadna Juarez-Garcia, Ruchika Sharma, Matthias Hunger, Sheena Kayaniyil, John R Penrod

Lung Cancer· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Three-year follow-up and patient-reported outcomes from CheckMate 078: Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer.
Jianhua Chang, Yi-Long Wu, Shun Lu, Jie Wang, Tony Mok, John R Penrod

Lung Cancer· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trends in treatment patterns and survival outcomes in advanced non-small cell lung cancer: a Canadian population-based real-world analysis.
Robert Carroll, Margherita Bortolini, Alan Calleja, Robin Munro, Shiying Kong, John R Penrod

BMC Cancer· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment patterns and outcomes for patients with malignant pleural mesothelioma in England in 2013-2017: A nationwide CAS registry analysis from the I-O Optimise initiative.
Paul Baas, Melinda J Daumont, Laure Lacoin, John R Penrod, Robert Carroll

Lung Cancer· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis